AbCellera Enters into a Collaboration Agreement with Prelude Therapeutics to Develop Antibody Drug Conjugated to Treat Cancer
Shots:
- AbCellera granted Prelude the exclusive worldwide rights to jointly discover, develop & commercialize up to 5 ADC programs targeting cancer indications
- As per agreement, AbCellera was held responsible for all the manufacturing activities & Prelude for the clinical development & global commercialization. Additionally, AbCellera also received the option to co-promote the products in the US
- The collaboration synergistically uses AbCellera's antibody discovery and development engine to generate precision ADCs with Prelude's targeted protein degradation & medicinal chemistry expertise for the treatment of cancer. The first program will enhance the reach of Prelude’s small molecule SMARCA2 selective degraders
Ref: AbCellera | Image: AbCellera
Related News:- Confo Therapeutics Entered into a Research Collaboration with AbCellera for GPCR-Targeting Antibody Discovery
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
